OPK vs. FOLD, LGND, GERN, MNKD, DVAX, BCRX, CLDX, NVAX, MYGN, and INVA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Dynavax Technologies (DVAX), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Myriad Genetics (MYGN), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
OPKO Health vs.
Amicus Therapeutics (NASDAQ:FOLD) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Amicus Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500.
OPKO Health has a net margin of -18.65% compared to Amicus Therapeutics' net margin of -21.21%. OPKO Health's return on equity of -9.76% beat Amicus Therapeutics' return on equity.
64.6% of OPKO Health shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 47.3% of OPKO Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Amicus Therapeutics received 24 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 73.10% of users gave Amicus Therapeutics an outperform vote while only 65.54% of users gave OPKO Health an outperform vote.
Amicus Therapeutics has higher earnings, but lower revenue than OPKO Health. Amicus Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, OPKO Health had 4 more articles in the media than Amicus Therapeutics. MarketBeat recorded 12 mentions for OPKO Health and 8 mentions for Amicus Therapeutics. OPKO Health's average media sentiment score of 1.07 beat Amicus Therapeutics' score of 0.25 indicating that OPKO Health is being referred to more favorably in the news media.
Amicus Therapeutics currently has a consensus price target of $16.88, indicating a potential upside of 79.33%. OPKO Health has a consensus price target of $2.75, indicating a potential upside of 87.07%. Given OPKO Health's stronger consensus rating and higher probable upside, analysts clearly believe OPKO Health is more favorable than Amicus Therapeutics.
Summary
OPKO Health beats Amicus Therapeutics on 12 of the 18 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OPKO Health Competitors List
Related Companies and Tools
This page (NASDAQ:OPK) was last updated on 1/21/2025 by MarketBeat.com Staff